| Company Name: |
BioBioPha Co., Ltd.
|
| Tel: |
0871-65217109 13211707573; |
| Email: |
y.liu@mail.biobiopha.com |
| Products Intro: |
Product Name:Cajanin
CAS:32884-36-9
Purity:98.0% Package:5mg Remarks:BBP02188
|
3-(2,4-Dihydroxyphenyl)-5-hydroxy-7-methoxy-4H-1-benzopyran-4-one manufacturers
|
| | 3-(2,4-Dihydroxyphenyl)-5-hydroxy-7-methoxy-4H-1-benzopyran-4-one Basic information |
| | 3-(2,4-Dihydroxyphenyl)-5-hydroxy-7-methoxy-4H-1-benzopyran-4-one Chemical Properties |
| Melting point | 208-210 °C(Solv: acetone (67-64-1)) | | Boiling point | 605.5±55.0 °C(Predicted) | | density | 1.512±0.06 g/cm3(Predicted) | | pka | 6.19±0.20(Predicted) | | form | Solid | | color | Off-white to light yellow |
| | 3-(2,4-Dihydroxyphenyl)-5-hydroxy-7-methoxy-4H-1-benzopyran-4-one Usage And Synthesis |
| Uses | Cajanin is a potent and orally active anti-melanogenic agent. Cajanin shows antiproliferative activity in MNT1 Cells. Cajanin efficiently decreases the melanin content. Cajanin down-regulates the mRNA and protein expression levels of MITF, tyrosinase, TRP-1 and Dct (TRP-2). Cajanin induces cell cycle arrest at G2/M and S phase. Cajanin stimulates osteoblast proliferation. Cajanin has the potential for the research of human hyperpigmented disorders and menopausal osteoporosis[1][2]. | | Definition | ChEBI: Cajanin is a member of 7-methoxyisoflavones. It has a role as a metabolite. | | in vivo | Cajanin (10 mg/kg, p.o.; daily for 30 consecutive days) increases the BMD levels in all anatomical regions of the skeleton studied in Sprague Dawley rats[1]. | | References | [1] Netcharoensirisuk P, et al. Cajanin Suppresses Melanin Synthesis through Modulating MITF in Human Melanin-Producing Cells. Molecules. 2021 Oct 5;26(19):6040. DOI:10.3390/molecules26196040
[2] Bhargavan B, et al. Methoxylated isoflavones, cajanin and isoformononetin, have non-estrogenic bone forming effect via differential mitogen activated protein kinase (MAPK) signaling. J Cell Biochem. 2009 Oct 1;108(2):388-99. DOI:10.1002/jcb.22264
[3] Wensaas AJ, et al. Fatty acid incubation of myotubes from humans with type 2 diabetes leads to enhanced release of beta-oxidation products because of impaired fatty acid oxidation: effects of tetradecylthioacetic acid and eicosapentaenoic acid. Diabetes. 2009 Mar;58(3):527-35. DOI:10.2337/db08-1043 |
| | 3-(2,4-Dihydroxyphenyl)-5-hydroxy-7-methoxy-4H-1-benzopyran-4-one Preparation Products And Raw materials |
|